Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, 75124, Uppsala, Sweden.
Department of Clinical Neuroscience, Karolinska Institute, 17177, Stockholm, Sweden.
Angew Chem Int Ed Engl. 2021 Aug 9;60(33):18022-18030. doi: 10.1002/anie.202101478. Epub 2021 Jul 16.
Many diseases are polygenic and can only be treated efficiently with drugs that modulate multiple targets. However, rational design of compounds with multi-target profiles is rarely pursued because it is considered too difficult, in particular if the drug must enter the central nervous system. Here, a structure-based strategy to identify dual-target ligands of G-protein-coupled receptors is presented. We use this approach to design compounds that both antagonize the A adenosine receptor and activate the D dopamine receptor, which have excellent potential as antiparkinson drugs. Atomic resolution models of the receptors guided generation of a chemical library with compounds designed to occupy orthosteric and secondary binding pockets in both targets. Structure-based virtual screens identified ten compounds, of which three had affinity for both targets. One of these scaffolds was optimized to nanomolar dual-target activity and showed the predicted pharmacodynamic effect in a rat model of Parkinsonism.
许多疾病是多基因的,只能用能调节多个靶点的药物有效治疗。然而,由于被认为太难,很少有针对多靶点特性的化合物进行理性设计,特别是如果药物必须进入中枢神经系统。此处提出了一种基于结构的策略,用于鉴定 G 蛋白偶联受体的双靶标配体。我们使用这种方法设计了既能拮抗 A 腺苷受体又能激活 D 多巴胺受体的化合物,它们具有作为抗帕金森病药物的优异潜力。受体的原子分辨率模型指导了化合物的化学文库的生成,这些化合物旨在占据两个靶点的正位和次要结合口袋。基于结构的虚拟筛选鉴定了 10 种化合物,其中 3 种对两个靶点均有亲和力。这些支架中的一个经过优化,具有纳摩尔级的双靶标活性,并在帕金森病大鼠模型中显示出预期的药效。